Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-475 with high-dose statins in primary hypercholesterolemia
2005-004876-19Phase 3Terminated
- Sponsor
- Takeda
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lapaquistat in hypercholesterolemia (6 arms), sponsored by Takeda. Primary endpoint: Change in plasma LDL-C at 24 weeks. Started Nov 2005; status: terminated.
02
Drugs
lapaquistat
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2005-004876-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004876-19.